

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/810,385	03/16/2001	Allen S. Laughon	WARF-0002	8778
26259 7	590 01/25/2005		EXAMINER	
LICATLA & TYRRELL P.C. 66 E. MAIN STREET			HARRIS, ALANA M	
MARLTON, NJ 08053			ART UNIT	PAPER NUMBER
,			1642	

DATE MAILED: 01/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/810,385	LAUGHON, ALLEN S.				
Office Action Summary	Examiner	Art Unit				
	Alana M. Harris, Ph.D.	1642				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a replection of the period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 10 N	November 2004.					
, <u> </u>	··					
	_					
Disposition of Claims						
4) ⊠ Claim(s) 1-4 is/are pending in the application. 4a) Of the above claim(s) is/are withdra 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-4 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or						
Application Papers						
9) The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list 	ts have been received. ts have been received in Application trity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s)/Mail Da					

DETAILED ACTION

Response to Amendment and Arguments

- 1. Claims 1-4 are pending.
 - Claims 1, 2 and 4 have been amended.
 - Claims 1-4 are examined on the merits.
- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Withdrawn Rejection

Claim Rejections - 35 USC § 112

3. The rejection of claims 1-4 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in light of the claim amendments.

Maintained Rejections and New Grounds of Rejections

Claim Rejections - 35 USC § 112

4. The rejection of claims 1-4 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed,

ŧ

Application/Control Number: 09/810,385

Art Unit: 1642

had possession of the claimed invention is maintained and newly made. THIS IS A NEW MATTER REJECTION.

The claims 1 and 2 continue to include the recitations, "containing interacting proteins comprising a Smad protein, a Smad protein co-repressor..." and "containing a Smad protein,", respectively. Furthermore, claims 1 and 2 have been amended to include the recitations "... a reporter with a Smad box-containing promoter..." and "of the reporter", respectively.

Applicant asserts the specification provides support for the claimed method including a Smad protein co-repressor, as well as the contemplation of interacting proteins. Applicant relies on the MPEP stating, "claimed subject matter need not be described literally..." and passages within the specification (see page 7, lines 17 and 18; page 14, lines 11-21) as support for the claims. The specification and these arguments submitted November 10, 2004 have been carefully considered, but found partially persuasive.

Applicant has pointed out several passages within their specification where they believe support for the questioned recitations and claimed methodology is listed. After review of the specific passages within the specification the Examiner does not concur. On page 7, lines 17 and 18 it is clear that Schnurri is a co-repressor, as well as the other DNA-bind Smad co-repressors (Evi-1, TGIF and SIP1). The Examiner does not refute that fact, however this section of the specification does not support the claimed method including cells containing interacting proteins comprising a Smad protein, a DNA-binding Smad co-repressor protein and a CtBP protein and the detection steps.

Page 4

The rejection set forth in the Action mailed August 10, 2004 makes note that Applicant has pointed out scientific observations such as that listed on page 7, but this does not exemplify an experimental design of the claimed assay. The steps listed in the claims are not of record in the specification.

Moreover, while it is true that the claimed subject matter need not be described literally it should be of record in the specification with the specific teachings as set forth in the claims. Namely at page 14, lines 11-21 there is the prophetic teaching that assays can be developed that interact with Smad protein to prevent interaction of CtBP with Smads or DNA-binding co-repressors or that interrupt the formation of a DNAbound complex containing Smads, CtBP and DNA-binding co-repressors, however this is not support for the claims specifically setting forth a method. The claims do not meet the written description requirement because the specification is remiss of active method steps including the cells containing interacting proteins and compounds necessitated for implementing the claimed method.

The amendments including the reporter and Smad-box containing promoter are not supported by the specification. Applicant directs the Examiner's attention to the paragraph bridging pages 14 and 15, however this section does list the reporter with a Smad box-containing promoter within cells containing specifically interacting proteins with the detection of transcription and the comparison between levels of transcription at precise points. Applicant has not pointed out where in the specification where these precise words or similar language are found in the context of the claimed method and its steps. Applicant is requested to pointedly express where support can be found or

Art Unit: 1642

delete the new matter at which time the 102(a) rejection set forth in the first action on the merits (FAOM), mailed May 6, 2003 may be reinstated. Applicant may obviate the instant rejection by concisely and precisely establishing claims inclusive of claim language, active steps and necessitated compounds fully of record in the specification.

5. Claims 1-4 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant broadly claims a method of identifying compounds that disrupts repression of transcript from genes utilizing a Smad protein or a Smad protein corepressor, as well as a number of proteins that are art known to act with the family of Smad proteins such as carboxyl terminus binding protein (CtBP) proteins. Applicant's method encompasses genes that have yet to be discovered or characterized, as well as any functional homologue of CtBP. The written description in this instant case only sets forth wild type dCtBP, see figure descriptions on pages 5 and 6 and does not disclose the plethora of genes that may be induced by TGF-β, activin or bone morphogenetic protein. The written description is not commensurate in scope with claims drawn to a method implementing any functional homologue CtBP protein from any species, which has not been defined by functional or structural characteristics and undefined genes.

Vas-Cath Inc. V. Mahurkar, 19 USPQ2d 1111, clearly states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117). The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116).

Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. 112 is severable from its enablement provision (see page 115).

With the exception of wild-type dCtBP, the skilled artisan cannot envision the detailed structure or function of the encompassed polypeptides and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Likewise, the skilled artisan cannot envision the detailed structure or function of the plethora of genes that may be induced by three distinct proteins. Adequate written description requires more than a mere statement that it is part of the invention and a reference to a potential method of isolating it. The polypeptides and molecules germane to the methodology itself are required. See *Fiers v. Revel*, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Lts.*, Furthermore, In *The Reagents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the court held that a generic statement, which defines a genus of nucleic acids by only their functional activity, does not provide an adequate written description of the genus. The court indicated that while Applicants are not required to disclose every species encompassed by a genus, the description of

Art Unit: 1642

a genus is achieved by the recitation of a representative number of DNA molecules, usually defined by a nucleotide sequence, falling within the scope of the claimed genus. At section B(1), the court states that "An adequate written description of a DNA...'requires a precise definition, such as by structure, formula, chemical name, or physical properties', not a mere wish or plan for obtaining the claimed chemical invention".

At the time the application was filed Applicants only had possession of dCtBP and not polypeptides that may or may not act in the manner suggested by the specification. The specification does not evidence the possession of all functional dCtBP molecules. Nor does the specification teach any genes that are induced by the three divergent molecules, TGF-β, activin or bone morphogenetic protein. There is insufficient support the generic claims as provided by the Interim Written Description Guidelines published in the June 15, 1998 Federal Register at Volume 63, Number 114, pages 32639-32645.

The full breadth of the claims does not meet the written description provision of 35 U.S.C. 112, first paragraph.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571)272-0831. The examiner works a flexible schedule, however she can normally be reached between the hours of 6:30 am to 5:30 pm, with alternate Fridays off.

Application/Control Number: 09/810,385 Page 8

Art Unit: 1642

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571) 272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ALANA M. HARRIS, PH.D. PRIMARY EXAMINER

Alana M. Harris, Ph.D.

19 January 2005